Compare AbbVie Inc (ABBV) vs SAP SE (SAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs SAP SE — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while SAP SE trades at $157.4 (market cap $191.33B). The key difference: AbbVie Inc is far larger — about 2.4× SAP SE's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | SAP | |
|---|---|---|
Market Cap | $449.91B | $191.33B |
Sector | Health | Technology |
52-Week High | $261.07 | $311.93 |
52-Week Low | $184.85 | $148.06 |
Enterprise Value | $513.38B | $188.85B |
Dividend Yield | 2.72% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
SAP trades at $162.77, up 0.11% with recent earnings beats driving positive momentum. The stock shows strong fundamentals with 19.58% net margins and consistent revenue growth to $36.8B in 2025. Technical indicators are mixed with bearish moving averages but neutral oscillators, while analyst consensus remains bullish with a $228.50 price target representing 40% upside potential from current levels.
SAP presents a compelling investment case with robust profitability and strategic AI investments, though near-term technical weakness and competitive pressures from Oracle's AI spending create headwinds. The company's cloud transition progress and strong cash flow generation support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
